biote Past Earnings Performance
Past criteria checks 1/6
biote's earnings have been declining at an average annual rate of -54.5%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 12.4% per year.
Key information
-54.5%
Earnings growth rate
-87.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 12.4% |
| Return on equity | n/a |
| Net Margin | 3.7% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How biote makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 193 | 7 | 95 | 0 |
| 30 Jun 24 | 187 | 4 | 93 | 0 |
| 31 Mar 24 | 187 | 8 | 89 | 0 |
| 31 Dec 23 | 185 | 3 | 89 | 0 |
| 30 Sep 23 | 184 | -3 | 83 | 0 |
| 30 Jun 23 | 181 | -10 | 80 | 0 |
| 31 Mar 23 | 173 | -8 | 154 | 0 |
| 31 Dec 22 | 165 | -1 | 146 | 0 |
| 30 Sep 22 | 158 | 3 | 145 | 0 |
| 30 Jun 22 | 152 | 11 | 142 | 0 |
| 31 Mar 22 | 145 | 24 | 60 | 0 |
| 31 Dec 21 | 139 | 33 | 56 | 0 |
| 30 Sep 21 | 133 | 37 | 47 | 0 |
| 31 Dec 20 | 117 | 29 | 40 | 0 |
| 31 Dec 19 | 110 | 21 | 43 | 0 |
Quality Earnings: BTMD has a large one-off loss of $19.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: BTMD became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BTMD's earnings have declined by 54.5% per year over the past 5 years.
Accelerating Growth: BTMD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BTMD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: BTMD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.